All times are listed in CEST (Central European Summer Time)
Found 1 Presentation For Request "1794P"
1794P - Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study)
- Virginia Calvo (Madrid, Spain)
Abstract
Background
Lung cancer remains a leading cause of cancer incidence and mortality worldwide. Small-cell lung cancer (SCLC) represents about 15% of all lung cancer, and more than two-thirds of SCLC patients are diagnosed with extensive stage (ES). SCLC is strongly associated with cigarette smoking. The Thoracic Tumors Registry (TTR) is an observational (patient registry), non-post-authorization, prospective cohort multicentre study promoted by the Spanish Lung Cancer Group.
Methods
This was an observational cohort multicentre study performed in Spain, including patients with lung cancer or other types of thoracic tumours. Enrolment took place between August 2016 and January 2020. Here we describe the characteristics of the patients diagnosed with extensive stage small-cell lung cancer.
Results
12,897 patients were registered in the TTR. A total of 1658 patients diagnosed with small-cell lung cancer (SCLC) were recruited at 67 Spanish hospitals. A total of 956 had extensive stage. Of these, 78.6% were male, median age 65 years (37-88). The vast majority of them were active smokers, 60.6% (579/956), or former smokers, 37.3% (357/956). ECOG performance status (PS) was 0, 1 and 2 (23.1%, 53% and 18.7%), respectively. Of 956 patients, 826 (86.4%) had some comorbidity, the most frequent were hypertension, dyslipidemia, chronic obstructive pulmonary disease (COPD) and diabetes mellitus. Most patients were symptomatic at diagnosis (92.3%, 882/956). The main symptoms were cough (39.4%), pain (36.7%) and dyspnea (35.6%), followed by weight loss (28.6%). At the time of diagnosis, 189 patients (19.8%) had brain metastases. Other locations of metastases were the liver (44.1%) and the bones (34.8%).
Conclusions
This study was conducted to assess the clinical reality of SCLC in Spain and has shown that it represents about 13% of all lung cancer cases, similar to the data described. Most of these patients are diagnosed with extensive stage (>50%) and are symptomatic at diagnosis. Our study also showed that SCLC is heavily related with smoking.
Legal entity responsible for the study
Fundacion GECP.
Funding
AstraZeneca, Novartis, Roche.
Disclosure
V. Calvo: Advisory/Consultancy: Roche; Advisory/Consultancy: BMS; Advisory/Consultancy: MSD; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Novartis; Advisory/Consultancy: Takeda. M. Provencio Pulla: Advisory/Consultancy: BMS; Advisory/Consultancy: Roche; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: MSD; Advisory/Consultancy: Takeda. All other authors have declared no conflicts of interest.